Since its clinical introduction, the anaphylactic potential of aprotinin has been a major concern. World wide, its use is expanding so there is an increased chance that patients have reexposure from various sources. The risk of anaphylaxis is approximately 2.8% in reexposed patients. From 1963 to 2003, 124 cases of aprotinin-induced anaphylaxis were reported in 61 publications. Eleven patients died. The reexposure interval was less than 3 months in 72% (38 of 53 patients). This review looks at the profile of patients at risk so preventive measures may be taken. Past and future exposures have to be taken into account before any aprotinin administration. © 2005 by The Society of Thoracic Surgeons.
Beierlein, W., Scheule, A. M., Dietrich, W., & Ziemer, G. (2005, February). Forty years of clinical aprotinin use: A review of 124 hypersensitivity reactions. Annals of Thoracic Surgery. https://doi.org/10.1016/j.athoracsur.2004.03.072